---
layout: default
title: Cetirizine Hcl
parent: 僅模型預測 (L5)
nav_order: 145
evidence_level: L5
indication_count: 0
---

# Cetirizine Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cetirizine HCl: Repurposing Evaluation — TxGNN Predictions Not Yet Available

## One-Sentence Summary

Cetirizine HCl is a second-generation H1-receptor antihistamine widely used in the UK for allergic rhinitis and chronic urticaria. The TxGNN prediction pipeline has not yet generated repurposing candidates for this compound, and UK MHRA regulatory records have not been loaded into this Evidence Pack. This report documents the current data status and defines the remediation steps required before a full repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Allergic rhinitis; chronic urticaria (known from drug class — not populated in Evidence Pack) |
| Predicted New Indication | Not yet available |
| TxGNN Prediction Score | Not yet available |
| Evidence Level | L5 — no predictions generated |
| UK Market Status | Not populated (known data gap — see note below) |
| Number of Marketing Authorisations | 0 recorded (data ingestion gap, not a true absence) |
| Recommended Decision | **Hold** |

> **Note on UK Market Status:** The Evidence Pack records zero UK licences, but Cetirizine HCl is well established in the UK marketplace as both a prescription medicine and a Pharmacy (P) / General Sale List (GSL) product. This is a data pipeline gap, not an accurate reflection of the MHRA register. UK marketing authorisation data must be loaded before this report can be used for any clinical or regulatory purpose.

---

## Why is This Prediction Reasonable?

This section cannot be completed at this time.

No TxGNN repurposing predictions have been generated for Cetirizine HCl. Until the prediction pipeline has been run and at least one candidate indication has been returned, there is no mechanistic or model-based rationale to evaluate.

Additionally, mechanism of action (MOA) data was not retrieved from DrugBank despite a reported successful query — this should be investigated as a data-processing issue in the pipeline.

---

## UK Market Information

No marketing authorisation records are available in this Evidence Pack.

This represents a data ingestion failure rather than the absence of UK licences. Cetirizine HCl is available in the UK under several brand names (e.g., Zirtek, Piriteze, Benadryl Allergy Solution) and as multiple generic products, classified under **BNF section 3.4.1 (Antihistamines)**. MHRA licence data should be retrieved and loaded before any regulatory assessment is undertaken.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Cetirizine HCl is missing its two most critical inputs — TxGNN repurposing predictions and UK MHRA regulatory records. No meaningful evaluation of a new indication can be performed without these foundations in place.

**To proceed, the following is needed:**

- **Run TxGNN prediction pipeline** for Cetirizine HCl to generate ranked repurposing candidates
- **Resolve DrugBank data gap** — the query returned a success status but no DrugBank ID or MOA was captured; inspect the mapping/parsing step in the pipeline
- **Load UK MHRA marketing authorisation records** via the regulatory data pipeline
- **Retrieve SmPC** for key warnings, contraindications, and drug interactions
- **Re-generate the Evidence Pack** once the above gaps are resolved, then repeat this evaluation

---

*This report is generated for research purposes only and does not constitute medical advice. Any repurposing candidates identified will require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

